• Peginterferon alfa-2b as monotherapy or in combination with lamivudine in patients with HBeAg-negative
  chronic hepatitis B: a randomised study.
  Papadopoulos VP, Chrysagis DN, Protopapas AN, et al 
  Med Sci Monit. 2009 Feb;15(2):CR56-61
  Abstract
• Peginterferon alpha 2-b Monotherapy and Peginterferon alpha 2-b plus Lamivudine
  Combinationa Therapy for Patients with Hepatitis B E-Antigen-Negative Chronic Hepatitis B
  Kaymakoglu S, Oguz D, Gur G, et al 
  Antimicrob Agents Chemother. 2007 May 21;
  Abstract
• Genotype B and younger patient age associated with better response to low-dose therapy:
  a trial with pegylated/nonpegylated interferon-alpha-2b for hepatitis B e antigen-positive
  patients with chronic hepatitis B in China.
  Zhao H, Kurbanov F, Wan MB, et al  
  Clin Infect Dis. 2007 Feb 15;44(4):541-8
  Abstract
• Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic
  hepatitis B: relation to treatment response.
  ter Borg MJ, van Zonneveld M, Zeuzem S, et al  
  Hepatology. 2006 Sep;44(3):721-7.
  Abstract
• Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients
  with chronic hepatitis B.
  Wursthorn K, Lutgehetmann M, Dandri M. et al 
  Hepatology. 2006 Sep;44(3):675-84.
  Abstract
•  A multicenter, randomized, open-label study of the safety and effectiveness of pegylated interferon
  alpha 2b and interferon alpha 2b in treating HBeAg positive chronic hepatitis B patients
  Zhao H, Si CW, Wei L, Wan MB, et al
  Zhonghua Gan Zang Bing Za Zhi. 2006 May;14(5):323-6.
  Abstract
• FULL-TEXT ARTICLE
  Pegylated IFN-alpha 2b added to ongoing lamivudine therapy in patients with lamivudine-resistant
   chronic hepatitis B.
  Vassiliadis T, Patsiaoura K, Tziomalos K, et al  
  World J Gastroenterol. 2006 Apr 21;12(15):2417-22
  Paper
• Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B:
   no additional benefit of combination with lamivudine.
  van Zonneveld M, Zondervan PE, Cakaloglu Y,et al
  Liver Int. 2006 May;26(4):399-405.
  Abstract
• 48 weeks pegylated interferon alpha-2a is superior to 24 weeks of pegylated interferon alpha-2b
  in achieving hepatitis B e antigen seroconversion in chronic hepatitis B infection.
  Hui CK, Lai LS, Lam P, et al 
  Aliment Pharmacol Ther. 2006 Apr 15;23(8):1171-8.
  Abstract
• Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is
  associated with HBV genotype.
  Flink HJ, van Zonneveld M, Hansen BE, et al
  Am J Gastroenterol. 2006 Feb;101(2):297-303.
  Abstract
• FULL-TEXT ARTICLE
  A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated
  interferon-alpha2b and lamivudine with lamivudine alone.
  Chan HL, Leung NW, Hui AY, et al
  Ann Intern Med. 2005 Feb 15;142(4):I30.
  PDF Paper
• Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic
  hepatitis B: a randomised trial.
  Janssen HL, van Zonneveld M, Senturk H, et al
  Lancet. 2005 Jan 8-14;365(9454):123-9.
  Abstract

Adverse Events

• Extensive psoriasis induced by pegylated interferon alpha-2b treatment for chronic hepatitis B.
  Ketikoglou I, Karatapanis S, Elefsiniotis I, et al
  Eur J Dermatol. 2005 Mar-Apr;15(2):107-9.